Enovis Corp Total Liabilities
Enovis Corp total liabilities. Based on the latest financial reports, Enovis Corp (ENOV) has total liabilities worth $2.29 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Enovis Corp liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Enovis Corp (2004–2025)
Total liabilities of Enovis Corp from 2004 to 2025. This chart illustrates how Enovis Corp's total liabilities have evolved over time, based on quarterly financial data.
Enovis Corp Competitors by Total Liabilities
The table below lists competitors of Enovis Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Reform Health Management and Services Group Co Ltd
SHE:000503
|
China | CN¥789.38 Million |
|
Glenveagh Properties PLC
IR:GVR
|
Ireland | €510.35 Million |
|
Fermi Inc.
NASDAQ:FRMI
|
USA | $731.48 Million |
|
Lemon Tree Hotels Limited
NSE:LEMONTREE
|
India | Rs22.06 Billion |
|
Ningbo Fujia Industrial Co Ltd
SHG:603219
|
China | CN¥1.27 Billion |
|
Ventyx Biosciences Inc
NASDAQ:VTYX
|
USA | $20.10 Million |
|
International General Insurance Holdings Ltd
NASDAQ:IGIC
|
USA | $1.51 Billion |
|
Wuxi Dk Electronic Materials Co Ltd
SHE:300842
|
China | CN¥10.63 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Enovis Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Enovis Corp.
Liquidity & Leverage Metrics
Enovis Corp Total Liabilities Ratios Explained
Enovis Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enovis Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enovis Corp (2004–2025)
The table below shows the annual total liabilities of Enovis Corp from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.34 Billion | +8.74% |
| 2024-12-31 | $2.15 Billion | +97.90% |
| 2023-12-31 | $1.09 Billion | +32.20% |
| 2022-12-31 | $823.45 Million | -78.64% |
| 2021-12-31 | $3.85 Billion | +2.41% |
| 2020-12-31 | $3.76 Billion | -3.43% |
| 2019-12-31 | $3.90 Billion | +24.63% |
| 2018-12-31 | $3.13 Billion | +4.43% |
| 2017-12-31 | $2.99 Billion | -9.04% |
| 2016-12-31 | $3.29 Billion | -5.30% |
| 2015-12-31 | $3.48 Billion | -10.69% |
| 2014-12-31 | $3.89 Billion | +1.33% |
| 2013-12-31 | $3.84 Billion | -3.31% |
| 2012-12-31 | $3.97 Billion | +341.85% |
| 2011-12-31 | $899.27 Million | +11.61% |
| 2010-12-31 | $805.71 Million | +0.17% |
| 2009-12-31 | $804.30 Million | +7.79% |
| 2008-12-31 | $746.14 Million | -11.54% |
| 2007-12-31 | $843.49 Million | +6.59% |
| 2006-12-31 | $791.33 Million | +11.75% |
| 2005-12-31 | $708.15 Million | +16.13% |
| 2004-12-31 | $609.79 Million | -- |
About Enovis Corp
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compres… Read more